We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.
Charlie Galvin is General Manager for the UK, Ireland, and Canada at Amicus Therapeutics.
Prior to this, Charlie gained a breadth of pharmaceutical experience in market access, policy, commercial management, and marketing roles at Amgen and then Pfizer. Charlie is passionate about making the UK a world leader in science and innovation and that this translates into making a meaningful difference for patients.
Championing this agenda is her mission in her cross-industry roles as chair of the Rare Disease Industry Group, member of the ABPI Board and an industry representative on the NICE methods review working group.
Are you ready to transform your skills and unlock your full potential? Now is the time to elevate your training.
Join Now